Comparison of the Effects of Clozapine, Olanzapine and Risperidone with Haloperidol on Fasting Blood Level of Glucose, Cholesterol and Triglyceride in Patients with Psychotic Disorders

Atypical antipsychotic drugs are first line treatment for psychotic disorders and well tolerated by the patients because of less extra pyramidal side effects and better efficacies. But there are different reports about metabolic dysfunctions that are associated with use of these drugs. So the aim of this study was to compare these side effects among atypical antipsychotic drugs (clozapine, olanzapine, risperidone) and haloperidol.METHODS In this cohort study psychotic patients (according to DSM IV criteria) due to their response to previous treatment regiment or new onset of disorder were received clozapine, olanzapine, risperidone (atypical group) and haloperidol (typical group). Patients who were resistant to other drugs treated with clozapine and bipolar patients received olanzapine. Fasting blood level of glucose, cholesterol and triglyceride of all patients were measured before initiating and six weeks after drug administration.

75 inpatients or out patients with variety of psychotic disorders enrolled the study, as 45 patients were in atypical and 30 in typical drug groups. Two groups were matched by age and sex. The mean level of fasting blood glucose, triglyceride and cholesterol of patients in atypical drug group before treatment was 90.7%±16.2, 144±35.5 and 163±25.1 mg/dl, respectively and in typical group it was 88.6±27, 162.3±38.5 and 164.2±25 mg/dl, respectively. The mean level of fasting blood glucose, triglyceride and cholesterol of patients in atypical drug group after treatment was 94.4±13.1, 168±50.8 and 168.6±33.5 mg/dl, respectively and in typical group was 92.9±27, 175.3±45.9 and 164±26.5 mg/dl, respectively that showed no significant difference.

Antipsychotic drugs (either typical or atypical) didn’t increase fasting blood level of glucose, cholesterol and triglyceride in psychotic patients.